RBC has lowered its price target for Alnylam Pharmaceuticals to $280 from $345, while reiterating an Outperform rating. This adjustment follows the company's third-quarter financial results, suggesting a re-evaluation of future growth prospects or valuation metrics by the analyst.
RBC's decision to cut Alnylam Pharmaceuticals' price target from $345 to $280, despite maintaining an 'Outperform' rating, indicates a revised outlook on the company's valuation. This adjustment likely stems from the company's recent third-quarter financial results, which may have presented a more conservative growth trajectory or introduced new valuation considerations for the analyst. For traders, this could lead to short-term downward pressure on ALNY shares as the market digests the lower price target, even with the continued positive rating. The long-term implications depend on whether the market views this as a temporary recalibration or a sign of underlying challenges, but the maintained 'Outperform' suggests RBC still sees upside potential from the current share price.